Snellen visual acuity was recorded at baseline and all subsequent injections. Changes from baseline were calculated at yearly intervals.

The primary outcome measure was mean change in letter score at 5, 6, and 7 years; secondary outcomes included the percentage of patients with 20/40 vision or better at 7 years and the mean change in letter score at each yearly time point based on baseline visual grouping ( 20/40 or better, 20/50-20/100, 20/200 or worse ).

Forty-four, 75, and 109 patients with 7, 6, and 5 years, respectively, of continuous treatment were identified.

Subanalysis revealed that the greatest visual gains at 5 and 7 years were seen in those patients with baseline visual acuity worse than 20/200 ( +24.5 and +25.5 letters ), followed by those with 20/50 to 20/100 vision ( +6.7 and +6.9 letters ), and finally those with 20/20 to 20/40 ( +3.7 and +3.4 letters ).

Patients received an average of 10.5 injections per year.

In conclusion, continuous fixed-interval dosing of anti-VEGF therapy in patients with exudative AMD results in favorable long-term preservation out to 7 years, with vision stabilizing or improving in 93.2% of eyes.
Additionally, 43.2% of patients maintained driving vision in the treatment eye at 7 years compared with 10.1% at baseline.
The data suggest better outcomes with continuous therapy over published results with sporadic, as-needed therapy. ( Xagena )